Gilead takes a hit after a closely-watched Covid-19 trial of remdesivir is quietly terminated, raising fresh doubts
Shares of Gilead took a 3% hit $GILD Wednesday after researchers noted that they had suspended one of the closely-watched Covid-19 studies for remdesivir in China.
Initially highlighted in a note from RBC Capital, an update on clinicaltrials.gov today stated that the Phase III for mild to moderate patients had to be terminated due to a lack of patients to enroll. The sponsor is Capital Medical University with the Chinese Academy of Medical Sciences listed as a collaborator.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.